SYK

Intuitive Surgical ISRG is set to release second-quarter results on July 16. The Zacks Consensus Estimate for sales is pegged at $2.81 billion, indicating year-over-year growth of 15%, and the same for earnings per share (EPS) implies an improvement of 13.2% to $2.48. The estimate for EPS has remained stable over the past seven days. In the last reported quarter, Intuitive Surgical delivered an earnings surprise of 20.19%. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.82%. Although ISRG’s top and bottom-line figures are likely to reflect strong growth during the second quarter, its shares have underperformed the Zacks Medical - Instrument industry as well as other robotic-surgery device makers — Stryker SYK, Zimmer Biomet ZBH, Globus Medical GMED and Stereotaxis STXS — so far this year. The stock has declined 27.4%, its industry has dipped 14.2%, and the S&P 500 Index has gained 9.5% in the same period. The share prices of SYK, ZBH, GMED and STXS have decreased 6.9%, 0.8%, 12.2% and 24.4%, respectively. YTD Price Performance Image Source: Zacks Investment Research While Stryker commercializes its Mako robotic system for orthopedic joint replacements, Zimmer Biomet has ROSA system, which is available for orthopedic and neurosurgical procedures. Globus Medical and Stereotaxis’ robotic portfolios include ExcelsiusGPS and Genesis systems, respectively, used for spine and cranial procedures, and endovascular interventions. The underperformance of the ISRG stock has led to a decline in its valuation multiples as well. The Price-to-Earnings Forward 12 Month (P/E F12M) valuation has fallen from a high of 96.05X at the beginning of 2025 to its current 37.12X, reflecting a significant decline despite robust earnings growth. At its current valuation multiples, the ISRG stock looks attractive amid its strong fundamentals. P/E F12M Valuation of ISRG vs Industry Image Source: Zacks Investment Research Despite consistently delivering double-digit revenue and earnings growth, Intuitive Surgical stock has remained under pressure this year as investors weigh near-term margin headwinds against its long-term growth story. The biggest concern stems from the ongoing rollout of the next-generation da Vinci 5 platform. Although customer adoption has exceeded expectations, the system currently carries lower margins...

With a market cap of $125.3 billion, Stryker Corporation (SYK) is a medical technology company that develops and markets innovative products and services for hospitals, healthcare providers, and patients across the United States and approximately 61 countries worldwide. The company operates through its MedSurg and Neurotechnology and Orthopaedics segments, offering a broad portfolio that includes surgical equipment, medical devices, robotic-assisted technologies, neurovascular solutions, and orthopedic implants. The Portage, Michigan-based company is slated to announce its fiscal Q2 2026 results after the market closes on Thursday, Jul. 30. Ahead of the event, analysts expect SYK to report an adjusted EPS of $3.49, up 11.5% from $3.13 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion. Jeff Bezos Says ‘We Don’t Have a Revenue Problem’ in America — Bottom Half Paying Just 3% of Taxes Means ‘We Can Find 3%’ SpaceX Has Massive Multiyear Put Options Volume As SPCX Falls Below IPO Price Intel Stock Is ‘Too Good to Ignore’ as HSBC Sets a New Street-High Price Target Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For fiscal 2026, analysts predict Stryker to report adjusted EPS of $14.98, a rise of 9.9% from $13.63 in fiscal 2025. Moreover, adjusted EPS is anticipated to grow 10.7% year-over-year to $16.58 in fiscal 2027. Shares of Stryker have dropped 16.3% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 20.1% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 19.5% return over the same period. Stryker's shares fell 6.5% following its Q1 2026 results on Apr. 30 after the company reported weaker-than-expected revenue of $6.02 billion and adjusted EPS of $2.60. The miss was primarily driven by softer demand for implants and medical devices used in complex spinal and orthopedic procedures, with its largest MedSurg and Neurotechnology segment generating $3.21 billion in sales, well below the analysts expectation, although Orthopaedics sales rose 6.3% to $2.81 billion, exceeding the forecast. While Stryker maintained its full-year adjusted EPS guidance of $14.90-$15.10, the earnings and revenue...

Johnson & Johnson's JNJ MedTech division, which includes orthopedics, surgery, cardiovascular, electrophysiology, vision and wound closure products, contributes roughly 36% to the company’s total revenues. J&J is repositioning its MedTech portfolio toward more innovative, faster-growing areas, most notably cardiovascular. With the acquisitions of Shockwave in 2024 and Abiomed in 2022, J&J has become a category leader in four of the largest and highest-growth cardiovascular intervention MedTech markets. J&J is the market leader in heart recovery, circulatory restoration and electrophysiology. J&J’s MedTech business has improved in the last four quarters, driven by the acquired cardiovascular businesses, Abiomed and Shockwave, as well as Surgical Vision and wound closure in Surgery. J&J’s electrophysiology business has also improved significantly in recent quarters, driven by new product launches, including Varipulse and better commercial execution. Investors are likely to have closely monitored the segment's performance in the second quarter to gauge whether these factors continue to drive MedTech’s growth. J&J is scheduled to report second-quarter 2026 results on July 15. In the first quarter of 2026, J&J delivered nearly $8.64 billion in sales in its MedTech segment, reflecting growth of 4.6% on an operational basis. The positive trend is expected to have continued in the second quarter. The MedTech business is expected to have seen strong momentum in three focus areas: Cardiovascular, Surgery and Vision in the second quarter, backed by increased adoption of newly launched products. Orthopedics is likely to have grown at a more moderate pace. However, the company continues to face headwinds in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program, which is a government-driven cost containment effort in China. Sales in China are likely to have been hurt by the impact of the VBP program in the second quarter. On the conference call, investors will also look for updates on the MedTech unit’s outlook for 2026. J&J had earlier said that it expects better growth in the MedTech business in 2026 than 2025 levels, driven by increased adoption of newly launched products across Cardiovascular, Surgery and Vision portfolios. Also, J&J expects continued impacts from VBP issues in China in 2026, mainly in the second half. Anothe...

Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results. The live webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available at Stryker’s website beginning approximately two hours after the live call ends. An accompanying press release that includes summary financial information for the second quarter will be issued at approximately 4:05 p.m. (Eastern time) and available at Stryker - Press Releases on the day of the webcast. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com. Contacts For investor inquiries:Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected] For media inquiries:Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy right now. On June 5, Leerink reduced its price target for Stryker Corporation (NYSE:SYK) to $407 from $410 while keeping an Outperform rating on the company’s stock. The firm changed its SYK model in response to new 10-Q filings following the company’s first-quarter 2026 results. The company fell short of analysts’ forecasts, reporting earnings per share of $2.60 vs an estimate of $2.98, with revenue of $6 billion coming below an expected $6.34 billion. Despite these challenges, Stryker Corporation (NYSE:SYK) has reiterated its 2026 projection. The fiscal 2026 earnings per share projection fell by $0.01, reflecting management’s statement that a significant portion of the revenue deficit in the first quarter due to a cyberattack is expected to be recovered in the second half of the year. The firm’s EPS expectations for fiscal 2027 and fiscal 2028 were reduced by about 1% to reflect the impact of the most recent disclosures. Leerink, however, stated that it still sees a solid risk/reward skew for Stryker Corporation (NYSE:SYK) and thinks the company is still among the better-positioned names in large-cap medical technology. Founded in 1981, Stryker Corporation (NYSE:SYK) is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopedics, MedSurg, and Neurotechnology and Spine. While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.

It has been about a month since the last earnings report for Prestige Consumer Healthcare (PBH). Shares have added about 3.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Prestige Consumer Healthcare due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. Prestige Consumer Healthcare posted fourth-quarter fiscal 2026 adjusted earnings per share of $1.23, down 6.8% from $1.32 a year ago. The figure missed the Zacks Consensus Estimate by 11.7%. GAAP earnings per share was $1.13 compared with $1.00 a year ago. For fiscal 2026, adjusted earnings per share was $4.38 compared with $4.52 in the previous year. Quarterly revenues totaled $281.6 million, down 5.0% year over year. The figure fell short of the Zacks Consensus Estimate by 4.3%. For fiscal 2026, the company generated total revenues of $1.09 billion, down 4.3% from the prior-year figure. North American OTC Healthcare’s revenues amounted to $234.5 million for the fiscal fourth quarter, down 5.8% year over year. The decrease was primarily due to lower Eye & Ear Care category sales caused by the limited ability to meet demand for Clear Eyes. International OTC Healthcare’s revenues totaled $47.1 million in the fiscal fourth quarter, down 1% year over year. The weaker revenue performance can be attributed to shipping disruptions in the Middle East and lower sales in the Eye & Ear Care category. The gross profit in the fiscal fourth quarter fell 13.9% year over year to $146.3 million. The gross margin contracted 539 basis points (bps) year over year to 51.9% due to a 6.5% increase in the cost of sales (excluding depreciation). During the quarter, advertising and marketing expenses declined 5.2% to $35.1 million, while general and administrative expenses increased 11.9% to $30.3 million. Operating income, excluding depreciation and amortization, totaled $80.9 million, reflecting a 13.4% decrease. The adjusted operating margin contracted 279 bps to 28.7%. Prestige Consumer exited the fiscal fourth quarter of 2026 with cash and cash equivalents of $63.9 million compared with $97.9 million a year ago. Prestige Consumer generated net cash provided by operating activities of $257.6 m...

Medtronic plc MDT enters fiscal 2027 with guidance calling for continued organic growth and modest adjusted earnings expansion. At roughly the mid-teens on forward earnings and with a 3.5% dividend yield, the setup can appeal to investors seeking steadier medical-device exposure. The long-term stance is Neutral because progress in growth platforms is being weighed against near-term headwinds. Tariffs, fuel and transportation costs, mix drag, currency exposure and competition remain the main checks on upside. For fiscal 2027, Medtronic guided for organic revenue growth of 6.75% to 7.25% and adjusted earnings per share of $5.90 to $6.00. The outlook includes a 53rd week and a full-year contribution from the Diabetes business while separation plans remain on track. Consensus expectations call for fiscal 2027 revenue of $38.62 billion and earnings per share of $5.96. With guidance and consensus close, the decision hinges on whether execution can hold up as costs and mix pressure the model. Image Source: Zacks Investment Research MDT trades at 13.7 times forward 12-month earnings versus 15.5 times for the Zacks sub-industry, 19.9 times for the Zacks sector and 21.5 times for the S&P 500. The discount suggests investors want clearer margin traction before paying up. Over the past five years, the stock has traded between 12.1 times and 22.9 times, with a median of 15.8 times. The $86 price target assumes 14.4 times forward earnings, implying only modest multiple support. Image Source: Zacks Investment Research Procedure-driven demand has been resilient. Fourth-quarter fiscal 2026 revenue rose 9.9% year over year to $9.81 billion and topped expectations as volumes stayed firm. Cardiac Ablation Solutions is the clearest growth driver, with sales up 78% worldwide and 124% in the United States, supported by Affera and Sphere-9 adoption. Cardiac Rhythm Management grew in the mid-single digits, supported by Micra, Aurora EV-ICD and OmniaSecure, keeping cardiovascular momentum constructive. Structural Heart has been uneven in the United States. The category was flat in the fourth quarter, and softer U.S. performance contributed to the variability in the outlook. Coronary declined, and stents fell into the low double digits due to multi-region pricing declines. Medical Surgical also faces bariatric and advanced stapling weakness tied to the shift toward robotic surgery, wh...

It has been about a month since the last earnings report for Insulet (PODD). Shares have lost about 8.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Insulet due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Insulet Corporation reported first-quarter 2026 adjusted earnings per share of $1.42, up 39.7% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 24.8%. GAAP earnings per share were $1.30 compared with 50 cents from the year-ago quarter. Revenues totaled $761.7 million, which beat the Zacks Consensus Estimate by 4.6%. The top line jumped 33.9% year over year and 30.1% at constant exchange rate or CER, which exceeded the company’s high end of the guidance range of 25-27%. Insulet updated its revenue guidance for full-year 2026. Total revenues are now projected to grow 21-23% at CER. The Zacks Consensus Estimate for the company’s 2026 revenues is currently pinned at $3.32 billion, implying 22.4% year-over-year growth. Adjusted EPS is expected to grow more than 25% year over year in 2026. The Zacks Consensus Estimate for the company’s 2026 EPS is currently pegged at $6.43, implying 29.4% year-over-year growth. For the second quarter, Insulet projects revenue growth of 20-22%. The consensus estimate for the company’s second-quarter revenues is currently pegged at $787.5 million, implying 21.3% year-over-year growth. Since the earnings release, investors have witnessed a upward trend in estimates review. At this time, Insulet has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Insulet has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Insulet is part of the Zacks Medical - Products...

The Cooper Companies COO is scheduled to report second-quarter fiscal 2026 results on June 4, after market close. The Zacks Consensus Estimate for sales is pegged at $1.05 billion, implying 5.2% year-over-year growth. The bottom-line estimate is pinned at $1.10 per share, suggesting growth of 14.6%. The EPS estimates have remained stable over the past seven days. Image Source: Zacks Investment Research The company delivered an earnings surprise of 6.8% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.11%. The Cooper Companies, Inc. price-eps-surprise | The Cooper Companies, Inc. Quote Our proven model does not conclusively predict an earnings beat for The Cooper Companies this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. COO’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank of COO: The company carries a Zacks Rank #2 at present. The Cooper Companies is expected to have delivered a solid fiscal second-quarter performance, supported by continued strength in its CooperVision business, ongoing momentum from new product launches and benefits from operational efficiency initiatives. Following a strong first quarter, management raised its full-year adjusted EPS guidance to $4.58-$4.66, reflecting confidence in underlying demand trends and execution across both business segments. The CooperVision (CVI) segment likely remained the primary growth driver during the quarter. The company is likely to have entered second-quarter fiscal 2026 with strong momentum in the Americas and EMEA, supported by expanding customer partnerships, branded contract wins and private-label launches. Continued adoption of premium daily silicone hydrogel lenses, particularly the MyDay portfolio, likely contributed to revenue growth. Management previously highlighted strong performance from MyDay multifocal, Energys and toric lenses, each benefiting from a favorable product mix and increasing market penetration. Myopia control products are...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker (SYK) is back in focus after mixed first quarter results, a disruptive cyberattack, and a series of analyst updates, even as the company rolls out new products and reorganizes parts of its business. See our latest analysis for Stryker. At a share price of US$307.63, Stryker’s short term share price return has been weak, with the stock down 20.6% over the past 90 days. The 5 year total shareholder return of 29.73% points to longer term gains and suggests recent momentum has faded as investors weigh the cyberattack, softer Q1 results and fresh product launches. If Stryker’s recent swings have you reassessing healthcare exposure, this could be a good time to see what else is out there through the 35 healthcare AI stocks With Stryker now trading well below recent analyst targets and carrying a relatively low value score of 2, the key question is whether recent setbacks have created an opening or if the market is already baking in its future growth? According to a widely followed narrative on Simply Wall St, Stryker’s fair value sits at $323, slightly above the last close of $307.63, framing the recent pullback as a modest discount rather than a severe dislocation. Read the complete narrative. The fair value hinges on a specific earnings recovery path, a steady view on free cash flow, and a tight link between profit growth and return on equity. Curious which assumptions matter most, and how they balance growth against valuation risk. Result: Fair Value of $323 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, recent cyber risk and the reminder that Stryker must meet fairly specific cash flow and earnings paths could quickly challenge this “easy ride” narrative. Find out about the key risks to this Stryker narrative. While the user narrative sees Stryker as modestly undervalued at $323, the market’s current P/E of 35.3x tells a tougher story. It sits above the fair ratio of 31.3x, the peer average of 29x, and the US Medical Equipment sector at 24.3x. If growth or margins slip, this premium may not leave much room for error. See what the numbers say about this price — find out in our valuation breakdown. Faced with mixed signals on valuation, growth and risk, it makes sense to look unde...

Stryker Corporation (NYSE:SYK) is one of the best robotic surgery stocks to buy. Barclays cut the price target on Stryker Corporation (NYSE:SYK) to $394 from $469 on May 4, maintaining an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 results were mixed and below the Street’s estimates. It also stated that a “significant back-end loaded ramp” is required to attain the company’s full-year guidance for the target cut. In a separate development, Truist cut the price target on Stryker Corporation (NYSE:SYK) to $380 from $395 on April 15, reaffirming a Hold rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated in a research note that a premium valuation is justified for the stock given its view of the company’s high-quality, above-average revenue growth profile. However, it also prefers to have higher conviction in EPS upside and faster earnings growth potential. Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services that help improve patient and health outcomes. Its operations are divided into the MedSurg and Neurotechnology and the Orthopedics and Spine segments. While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None. Follow Insider Monkey on Google News.

With pharma and medtech Q1 earnings season now at a close, some sector areas performed better than others. In this episode, Robert Barrie, editor for Pharmaceutical Technology, and Ross Law, reporter at Medical Device Network, discuss the key trends from the quarter. In pharma, weight loss therapies and patent expirations dominated bottom lines. Eli Lilly's Mounjaro (tirzepatide) became the top-selling drug in the quarter, ousting MSD's Keytruda (pembrolizumab) in a changing of the guard. Meanwhile, the looming patent cliff is placing emphasis on late-stage pipelines and dealmaking activity for many companies. In medtech, geopolitical pressures meant some companies chose to revise their 2026 outlook. Trade through the Strait of Hormuz, one of the world’s most critical maritime chokepoints, has ongoing disruption, meaning the shipping of goods is currently more expensive. You can listen to the episode here: https://open.spotify.com/episode/30ko8xqvsSRLoyvwxWDTwM?si=3c2e38ebe6cc4d46 Eli Lilly, Novartis, GE HealthCare, and Stryker, amongst others, are covered. "Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.